Forum Archive Index - February 2000

[Derek Watt <dkw@paradise.net.nz>]

Thanks Hugh for your tip on Genesis

Actually if I'd known that they were listed I'd have bought them 
long before now (which shows my ignorance of the secondary sharemarket).
Maybe as a scientist I am attracted to companies like this.
I bought some the day after your message at $4.60 (monday 6th)
today (11th) they closed at about $5.85

I think that this share is bullet-proof, the company is self-made
created by a handful of people who left the Auckland Medical School
(molecular biology department) about 7 years ago, now employs 100 people etc
(see hughs post below).

They have a good core business (genome sequencing etc) + real prospects 
for future growth (pharmaceuticals in trials, listing on the NASDAQ etc),
the CEO has a stake in the company, has vision and 
obviously the ability to carry it out.

As for the figures I could use some help here, but to be honest I think
that the best is yet to come from this company.

There's a little more info at this site

http://www.biotech.org.nz/dir/genesis.htm

I searched but couldn't find any company web page.

Cheers,
Derek





>Subject: [sharechat] Selectivity & Positivity v Negativity 
>From: "hugh webber" <hugh.webber@clear.net.nz> 
>Date: Sun, 6 Feb 2000 12:24:33 +1300 
>
>---------------------------------------------------------------------------
--->--  cut

>I mention Genesis here (and I don't hold any shares in them) because they
>actually have some
>sort of concrete foundation unlike say SPE and AQL.
>Genesis has just got permission from the US FDA Admin to start phase 2
>clinical trials of psoriasis vaccine PVAC ( the culmination of 5 years
>laboratory and clinical work) and 6 months of regulatory
>processes.Psoriasis affects 1% to 3% of the world's population.
>It also is involved in developing an asthma drug with Wgtn's Malaghan
>Institute. Gen has 100 staff, half of them scientists from more than a
>dozen different countries.
>Genesis has moved from $2.90 at the start of the month to $4. Its
>development partner in the US, Corixa rose 88% in the month to $US32.
>Cavill White says if Genesis logically moved in tandem then it would be
>worth $12. Genesis last year announced plans to list on the NASDAQ.
>That's what I see as positivity. Wouldn't it be great to see a discussion
>about Genesis displacing SPE and AQL?
>cheers,
>Hugh 



----------------------------------------------------------------------------
http://www.sharechat.co.nz/          New Zealand's home for market investors
To remove yourself from this list, please us the form at
http://www.sharechat.co.nz/forum.html.



-----------------------------------
Derek Watt
http://members.tripod.com/DKWatt/
-----------------------------------




----------------------------------------------------------------------------
http://www.sharechat.co.nz/          New Zealand's home for market investors
To remove yourself from this list, please us the form at
http://www.sharechat.co.nz/forum.html.